Basilea Pharmaceutica Aktie 1143244 / CH0011432447
46.30
CHF
0.25
CHF
0.54%
10:00:02
SWX
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
| Ausblick | ||||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 91.18 |
| Basilea Pharmaceutica AG | 8.73 |
| Braginsky Family Office AG | 3.01 |
| Acatis Datini Valueflex Fonds | 2.37 |
| Government Pension Fund - Global (The) | 2.08 |
| CI Black Creek International Equity Fund | 1.87 |
| United Financial-International Equity Alpha Corporate Class | 1.62 |
| Vanguard Total International Stock Index Fund | 1.17 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 227 | 225 | 150 | 154 | 154 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.58 | 0.60 | 0.85 | 0.96 | 0.96 |
Bilanz (in Mio. EUR) - Aktiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 275 | 185 | 224 | 241 | 175 |
| Summe Anlagevermögen | 130 | 105 | 140 | 160 | 166 |
| Summe Aktiva | 282 | 221 | 230 | 247 | 221 |
Bilanz (in Mio. EUR) - Passiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 197 | 198 | 242 | 219 | 187 |
| Summe Fremdkapital | 348 | 314 | 332 | 306 | 242 |
| Summe Eigenkapital | -67 | -93 | -102 | -59 | -21 |
| Summe Passiva | 282 | 221 | 230 | 247 | 221 |
Adresse
| Hegenheimermattweg 167b, 4123 Allschwil | |
| Telefon | +41 (61) 606-11-11 |
| Fax | +41 (61) 606-11-12 |
| URL | http://www.basilea.com |
Management
|
Adesh Kaul
Chief Financial Officer |
|
Alf Gunnar Martin Nicklasson
Independent Non-Executive Director |
|
Carole A. Sable
Director |
|
Damian Heller
Secretary & General Counsel |
|
David Veitch
Chief Executive Officer |
|
Domenico Scala
Chairman |
|
Gerrit Hauck
Chief Technology Officer |
|
Laurenz Kellenberger
Chief Scientific Officer |
|
Leonard Kruimer
Independent Director |
|
Marc Engelhardt
Chief Medical Officer |
|
Nicole M. Onetto
Independent Non-Executive Director |
|
Peer Nils Schröder
Head-Corporate Communications & Investor Relations |
|
Steven D. Skolsky
Independent Non-Executive Director |
|
Thomas Werner
Vice Chairman |
|
Ursula Eberhardt
Head-Global Human Resources |